Bacterial infections exacerbate myeloma bone disease

Multiple myeloma is characterized by osteolytic lesions caused by reduced bone formation and activated bone resorption. An important feature of myeloma is a failure of bone healing after successful treatment. In this work, clinical studies indicated a highly positive correlation between bone marrow bacteria abundance and bone lesion numbers of myeloma patients in complete remission. Coculture experiments demonstrated that marrow Escherichia coli (E. coli) promotes osteoclast differentiation and inhibits osteoblast differentiation. Mechanism studies showed that E. coli lipopolysaccharides (LPS) activated NF-kappa B p65 signaling and reduced phosphorylated smad1/5/9 binding ability with RUNX2 promoter, leading to decreased RUNX2 expression in osteoblast progenitors. Additionally, LPS enhanced phosphorylated NF-kappa B p65 binding ability with NFATc1 promoter, leading to increased NFATc1 expression in osteoclast progenitors. In vivo studies revealed E. coli contributes to osteolytic bone lesion, and elimination of E. coli infection assists healing of bone lesion in mouse model of myeloma in complete remission. These findings establish a heretofore unrecognized effect for E. coli in the genesis of myeloma bone disease and suggest a new treatment strategy.

Automated summary

This study found a strong correlation between the abundance of Escherichia coli (E. coli) in bone marrow and the number of bone lesions in multiple myeloma patients. Further experiments showed that E. coli promotes osteoclast differentiation and inhibits osteoblast differentiation. Mechanism studies revealed that the lipopolysaccharides (LPS) produced by E. coli affect signaling pathways involved in bone formation and resorption. In vivo studies also demonstrated that eliminating E. coli infection helps in the healing of bone lesions in multiple myeloma patients.